Olav Hellebø

Olav Hellebø, CEO,  is an experienced pharmaceutical executive who has held senior positions in the pharmaceutical industry in both Europe and the USA.

He joins Clavis Pharma from UCB, the global biopharmaceutical company where he was Senior Vice President, UCB Pharma and President of Immunology Operations.  In this position he built and led the global organization responsible for the successful registration and launch of Cimzia^®, UCB's new antibody drug for the treatment of rheumatoid arthritis and Crohn's disease.

From 2003 to 2004 Mr Hellebø was Chief Operating Officer of Novartis UK and prior to that held a series of senior international roles at Schering Plough, the last as head of Schering Plough's Oncology Biotech Division in the USA.

Mr Hellebø graduated in business studies from Hofstra University, New York and received an MBA from IESE, Barcelona.